STOCK TITAN
  1. Home
  2. News
  3. MEIP

MEI Pharma Inc - MEIP STOCK NEWS

Welcome to our dedicated news page for MEI Pharma (Ticker: MEIP), a resource for investors and traders seeking the latest updates and insights on MEI Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MEI Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MEI Pharma's position in the market.

News
MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023
Rhea-AI Summary
MEI Pharma announced that clinical data from the Phase 1 study of voruciclib will be presented at the ASH Annual Meeting. The study evaluates the CDK9 inhibitor alone and in combination with venetoclax in patients with AML or B-cell malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
none
-
News
MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital
Rhea-AI Summary
MEI Pharma and Anson Funds and Cable Car Capital have entered into a cooperation agreement. MEI Pharma plans to pay a dividend of $1.75 per share to stockholders and authorize a second return of capital of approximately $9.33 million. The company has appointed two directors designated by Anson and Cable Car and formed a Capital Allocation Committee. Anson and Cable Car have agreed to withdraw their consent solicitation and vote for the company's director nominees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.93%
Tags
none
-
News
MEI Pharma Recommends Stockholders Not to Consent
Rhea-AI Summary
MEI Pharma files definitive consent revocation statement and urges stockholders to disregard Anson Advisors and Cable Car Capital's consent solicitation materials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
none
News
MEI Pharma Adopts Limited-Duration Stockholder Rights Plan
Rhea-AI Summary
MEI Pharma adopts a limited-duration stockholder rights plan in response to Anson Advisors and Cable Car Capital accumulating approximately 19.9% of outstanding shares. The plan aims to protect stockholders' long-term value and prevent a self-interested group from taking control. The plan becomes exercisable if any person acquires 20% or more of the company's outstanding common stock. The Rights Plan is effective immediately and will expire on September 30, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
none
-
News
MEI Pharma Issues Statement Regarding Anson and Cable Car’s Opportunistic Actions
Rhea-AI Summary
MEI Pharma, Inc. responds to consent solicitation by Anson Advisors Inc. and Cable Car Capital LLC. Board focused on advancing voruciclib and ME-344 programs with potential to improve cancer outcomes. Anson and Cable Car's agenda to strip cash and lack of understanding of MEI's business raises concerns. MEI Board evaluates request for new record date and finds no basis. MEI to provide formal recommendation on consent solicitation and election of directors in upcoming SEC filings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.64%
Tags
none
-
News
MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights
Rhea-AI Summary
MEI Pharma reports fiscal year 2023 results, expects data readouts from ongoing clinical studies in 2024. ME-344 in combination with Avastin in colorectal cancer and voruciclib in combination with Venclexta in acute myeloid leukemia. Positive data would support further development. MEI had $100.7 million in cash, cash equivalents, and short-term investments with no debt as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
earnings
News
MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023
Rhea-AI Summary
MEI Pharma to release fiscal year end financial results on September 26, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.92%
Tags
conferences earnings
-
News
MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car
Rhea-AI Summary
MEI Pharma, Inc. responds to director nomination, highlights progress in clinical development and commitment to stockholders
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
-
News
MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer
Rhea-AI Summary
MEI Pharma has announced the dosing of the first patient in a Phase 1b study evaluating ME-344 in combination with bevacizumab in patients with previously treated metastatic colorectal cancer. ME-344 is a mitochondrial inhibitor targeting energy production, while bevacizumab is a VEGF inhibitor. The study aims to evaluate the combination's potential to inhibit energy production in tumor cells and induce an antitumor effect. Safety and efficacy data from the first cohort of patients are expected in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
clinical trial
News
MEI Pharma Announces Results of Special Meeting of Stockholders
Rhea-AI Summary
MEI Pharma, Inc. (NASDAQ: MEIP) announced the termination of the merger agreement with Infinity Pharmaceuticals, Inc. due to not obtaining the necessary stockholder votes. The certified results showed that 47.86% voted in favor, and 51.44% against. MEI remains focused on its current development pipeline, including Voruciclib and ME-344, with clinical data expected by year-end. MEI's clinical-stage development programs have the potential to improve patient outcomes in cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock MEIP logo
MEI Pharma Inc

Nasdaq:MEIP

MEIP Rankings

#5108 Ranked by Market Cap
#1883 Ranked by Stock Gains
N/A Ranked by Dividends

MEIP Stock Data

21.79M
4.94M
0.54%
47.58%
0.12%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About MEIP

mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com.